REFERENCES

• Machado-VieiraR.SalvadoreG.IbrahimLA.az-GranadosN.ZarateCA.Jr.Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.Curr Pharm Des.2009151595161119442176
   PubMed Web of Science ®Google Scholar
• SwerdlowNR.van BergeijkDP.BergsmaF.WeberE.TalledoJ.The effects of memantine on prepulse inhibition.Neuropsychopharmacology.2009341854186419242406
   PubMed Web of Science ®Google Scholar
• MyintAM.KimYK.VerkerkR.ScharpeS.SteinbuschH.LeonardB.Kynurenine pathway in major depression: evidence of impaired neuroprotection.J Affect Disord.20079814315116952400
   PubMed Web of Science ®Google Scholar
• MüllerN.SchwarzMJ.The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.J Neurotransmission.2007(suppl)269280
   Google Scholar
• MillierN.SchwarzMJ.The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.Mol Psychiatry.200712988100017457312
   PubMed Web of Science ®Google Scholar
• MillsCD.KincaidK.AltJM.HeilmanMJ.HillAM.M-1/M-2 macrophages and the Th1/Th2 paradigm.J Immunol.20001646166617310843666
   PubMed Web of Science ®Google Scholar
• BrownAS.BeggMD.GravensteinS.et al.Serologic evidence of prenatal influenza in the etiology of schizophrenia.Arch Gen Psychiatry.20046177478015289276
   PubMed Web of Science ®Google Scholar
• BukaSL.GoldsteinJM.SeidmanLJ.TsuangMT.Maternal recall of pregnancy history: accuracy and bias in schizophrenia research.Schizophr Bull.20002633535010885635
   PubMed Web of Science ®Google Scholar
• ZuckermanL.WeinerI.Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring.J Psychiatr Res.20053931132315725430
   PubMed Web of Science ®Google Scholar
• GattazWF.AbrahaoAL.FoccaciaR.Childhood meningitis, brain maturation and the risk of psychosis.Eur Arch Psychiatry Clin Neurosci.2004254232614991375
   PubMed Web of Science ®Google Scholar
• KoponenH.RantakallioP.VeijolaJ.JonesP.JokelainenJ.IsohanniM.Childhood central nervous system infections and risk for schizophrenia.Eur Arch Psychiatry Clin Neurosci.200425491314991373
   PubMed Web of Science ®Google Scholar
• BrownAS.The risk for schizophrenia from childhood and adult infections.Am J Psychiatry.200816571018178749
   PubMed Web of Science ®Google Scholar
• DalmanC.AllebeckP.GunnellD.et al.Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects.Am J Psychiatry.2008165596518056223
   PubMed Web of Science ®Google Scholar
• KörschenhausenDA.HampelHJ.AckenheilM.PenningR.MüllerN.Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes.Schizophr Res.1996191031098789908
   PubMed Web of Science ®Google Scholar
• BechterK.Mild encephalitis underlying psychiatric disorders - A reconsideration and hypothesis exemplified on Borna disease.Neurol Psychiatry Brain Res.200195570
   Google Scholar
• ReichenbergA.KrausT.HaackM.SchuldA.PollmacherT.YirmiyaR.Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion.Psychoneuroendocrinology.20022794595612383455
   PubMed Web of Science ®Google Scholar
• ReichenbergA.YirmiyaR.SchuldA.et al.Cytokine-associated emotional and cognitive disturbances in humans.Arch Gen Psychiatry.20015844545211343523
   PubMed Web of Science ®Google Scholar
• WilkeI.AroltV.RothermundtM.WeitzschC.HornbergM.KirchnerH.Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.Eur Arch Psychiatry Clin Neurosci.19962462792848863007
   PubMed Web of Science ®Google Scholar
• MüllerN.RiedelM.AckenheilM.SchwarzMJ.Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation.World J Biol Psychiatry.2000117317912607212
   PubMedGoogle Scholar
• Sperner-UnterwegerB.MillerC.HolznerB.WidnerB.FleischhackerWW.FuchsD.Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Müller N, ed;Psychiatry, Psychoiinrnunology. and Viruses. Vienna, Austria; New York, NY: Springer;1999115119
   Google Scholar
• MüllerN.AckenheilM.HofschusterE.MempelW.EcksteinR.Cellular immunity in schizophrenic patients before and during neuroleptic treatment.Psychiatry Res.1991371471601678892
   PubMed Web of Science ®Google Scholar
• SchwarzMJ.RiedelM.AckenheilM.MüllerN.Decreased levels of soluble intercellular adhesion molecule-1 (slCAM-1) in unmedicated and medicated schizophrenic patients.Biol Psychiatry.200047293310650446
   PubMed Web of Science ®Google Scholar
• HaackM.Hinze-SelchD.FenzelT.et al.Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.J Psychiatr Res.19993340741810504009
   PubMed Web of Science ®Google Scholar
• MolholmHB.Hyposensitivity to foreign protein in schizophrenic patients.Psychiatr Quarterly.194216565571
   Google Scholar
• RiedelM.SpellmannI.SchwarzMJ.StrassnigM.SikorskiC.MôllerHJ.MüllerN.Decreased T cellular immune response in schizophrenic patients.J Psychiatr Res.2006413716434055
   PubMed Web of Science ®Google Scholar
• BreseeC.RapaportMH.Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia.Int J Neuropsychopharmacol.20091286186519366488
   PubMed Web of Science ®Google Scholar
• PotvinS.StipE.SepehryAA.GendronA.BahR.KouassiE.Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.Biol Psychiatry.20086380180818005941
   PubMed Web of Science ®Google Scholar
• CazzulloCL.ScaroneS.GrassiB.et al.Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.Prog Neuropsychopharmacol Biol Psychiatry.1998229479579789879
   PubMed Web of Science ®Google Scholar
• LinA.KenisG.BignottiS.et al.The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.Schizophr Res.1998329159690329
   PubMed Web of Science ®Google Scholar
• Sperner-UnterwegerB.WhitworthA.KemmlerG.et al.T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients.Schizophr Res.199938617010427611
   PubMed Web of Science ®Google Scholar
• SchwarzMJ.ChiangS.MüllerN.AckenheilM.T-helper-1 and T-helper2 responses in psychiatric disorders.Brain Behavlmmun.200115340370
   Web of Science ®Google Scholar
• van KammenDP.McAllister-SistilliCG.KelleyME.Relationship between immune and behavioral measures in schizophrenia. In: Wieselmann G, ed.Current Update in Psychoirnrnunohgy. Vienna, Austria; New York, NY: Springer;19975155
   Google Scholar
• MittlemanBB.CastellanosFX.JacobsenLK.RapoportJL.SwedoSE.ShearerGM.Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease.J Immunol.1997159299429999300724
   PubMed Web of Science ®Google Scholar
• MüllerN.HofschusterE.AckenheilM.MempelW.EcksteinR.Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis.Prog Neuropsychopharmacol Biol Psychiatry.1993177137308255983
   PubMed Web of Science ®Google Scholar
• MaesM.MeltzerHY.BuckleyP.BosniansE.Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.Eur Arch Psychiatry Clin Neurosci.19952443253297772617
   PubMed Web of Science ®Google Scholar
• IrwinM.Immune correlates of depression.Adv Exp Med Biol.199946112410442164
   PubMed Web of Science ®Google Scholar
• MüllerN.SchwarzMJ.Immunology in anxiety and depression. In: Kasper S, den Boer JA, Sitsen JMA, eds.Handbook of Depression and Anxiety,2nd ed. New York, NY: Marcel Dekker;2002267288
   Google Scholar
• MikovaO.YakimovaR.BosniansE.KenisG.MaesM.Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis.Eur Neuropsychopharmacol.20011120320811418279
   PubMed Web of Science ®Google Scholar
• SluzewskaA.RybakowskiJ.BosmansE.et al.Indicators of immune activation in major depression.Psychiatry Res.1996641611678944394
   PubMed Web of Science ®Google Scholar
• RothermundtM.AroltV.FenkerJ.GutbrodtH.PetersM.KirchnerH.Different immune patterns in melancholic and non-melancholic major depression.Eur Arch Psychiatry Clin Neurosci.2001251909711407444
   PubMed Web of Science ®Google Scholar
• BonaccorsoS.LinAH.VerkerkR.et al.Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers.J Affect Disord.19984875829495605
   PubMed Web of Science ®Google Scholar
• MaesM.ScharpeS.MeltzerHY.et al.Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response.Psychiatry Res.1994541431607761549
   PubMed Web of Science ®Google Scholar
• MaesM.ScharpeS.MeltzerHY.et al.Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamicpituitary-adrenal axis in severe depression.Psychiatry Res.19934911277511248
   PubMed Web of Science ®Google Scholar
• SchiepersOJ.WichersMC.MaesM.Cytokines and major depression.Prog Neuropsychopharmacol Biol Psychiatry.20052920121715694227
   PubMed Web of Science ®Google Scholar
• MyintAM.LeonardBE.SteinbuschHW.KimYK.Th1, Th2, and Th3 cytokine alterations in major depression.J Affect Disord.20058816717316126278
   PubMed Web of Science ®Google Scholar
• JunTY.PaeCU.HoonH.ChaeJH.BahkWM.KimKS.SerrettiA.Possible association between - G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population.Psychiatr Genet.20031317918112960751
   PubMed Web of Science ®Google Scholar
• RieckmannP.NunkeK.BurchhardtM.et al.Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier.J Neuroimmunol.1993471331408103775
   PubMed Web of Science ®Google Scholar
• SchäferM.HornM.SchmidtF.et al.Correlation between slCAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.Brain Behav lmmun.200418555562
   PubMed Web of Science ®Google Scholar
• ThomasAJ.FerrierIN.KalariaRN.et al.Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex.Am J Psychiatry.20001571682168411007725
   PubMed Web of Science ®Google Scholar
• DimopoulosN.PiperiC.SaloniciotiA.et al.Elevation of plasma concentration of adhesion molecules in late-life depression.Int J Geriatr Psychiatry.20062196597116927406
   PubMed Web of Science ®Google Scholar
• MendlovicS.MozesE.EilatE.et al.Immune activation in non-treated suicidal major depression.Immunol Lett.19996710510810232390
   PubMed Web of Science ®Google Scholar
• PenttinenJ.Hypothesis: low serum cholesterol, suicide, and interleukin2. Am J Epidemiol.19951417167187709913
   PubMed Web of Science ®Google Scholar
• NassbergerL.Traskman-BendzL.Increased soluble interleukin-2 receptor concentrations in suicide attempters.Acta Psychiatr Scand.19938848528372695
   PubMed Web of Science ®Google Scholar
• BaronDA.HardieT.BaronSH.Possible association of interleukin-2 treatment with depression and suicide.J Am Osteopath Assoc.1993937998008365929
   PubMedGoogle Scholar
• MüllerN.RiedelM.SchwarzMJ.et al.Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia. In Wieselmann G, ed.Current Update in Psychoimmunology. Vienna, Austria; New York, NY: Springer;19975767
   Google Scholar
• MüllerN.EmplM.RiedelM.SchwarzM.AckenheilM.Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.Eur Arch Psychiatry Clin Neurosci.19972473083139477010
   PubMed Web of Science ®Google Scholar
• MüllerN.RiedelM.HadjamuM.SchwarzMJ.AckenheilM.GruberR.Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia.Am J Psychiatry.199915663463610200747
   PubMed Web of Science ®Google Scholar
• PollmächerT.SchuldA.KrausT.HaackM.Hinze-SelchD.[On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors].Fortschr Neurol Psychiatr.200169(suppl 2)S65S7411533853
   PubMed Web of Science ®Google Scholar
• OzekM.ToreciK.AkkokI.GuvenerZ.[Influence of therapy on antibody-formation],Psychopharmacologia.1971214014125098938
   PubMedGoogle Scholar
• TanakaKF.ShintaniF.FujiiY.YagiG.AsaiM.Serum interleukin-18 levels are elevated in schizophrenia.Psychiatry Res.200096758010980328
   PubMed Web of Science ®Google Scholar
• MaesM.BosmansE.De JonghR.KenisG.VandoolaegheE.NeelsH.Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.Cytokine.199798538589367546
   PubMed Web of Science ®Google Scholar
• SongC.LeonardBE.An acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment.Med Sci Res.199422313314
   Google Scholar
• ZhuJ.BengtssonBO.MixE.ThorellLH.OlssonT.LinkH.Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN).Immunopharmacology.1994272252448071062
   PubMedGoogle Scholar
• MaesM.SongC.LinAH.BonaccorsoS.et al.Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion.Neuropsychopharmacology.19992037037910088138
   PubMed Web of Science ®Google Scholar
• SeidelA.AroltV.HunstigerM.RinkL.BehnischA.KirchnerH.Cytokine production and serum proteins in depression.Scand J Immunol.1995415345387539545
   PubMed Web of Science ®Google Scholar
• LanquillonS.KriegJC.Bening-Abu-ShachU.VedderH.Cytokine production and treatment response in major depressive disorder.Neuropsychopharmacology.20002237037910700656
   PubMed Web of Science ®Google Scholar
• KenisG.MaesM.Effects of antidepressants on the production of cytokines.Int J Neuropsychopharmacol.2002540141212466038
   PubMed Web of Science ®Google Scholar
• O'SullivanJB.RyanKM.CurtinNM.HarkinA.ConnorTJ.Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration.Int J Neuropsychopharmacol.20091268769919046481
   PubMed Web of Science ®Google Scholar
• VollmarP.NesslerS.KalluriSR.HartungHP.HemmerB.The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines.Int J Neuropsychopharmacol.20091252553618922202
   PubMed Web of Science ®Google Scholar
• SluzewskaA.RybakowskiJK.LaciakM.et al.lnterleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.Ann N Y Acad Sci.19957624744767668562
   PubMed Web of Science ®Google Scholar
• FrommbergerUH.BauerJ.HaselbauerP.FraulinA.RiemannD.BergerM.lnterleukln-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission.Eur Arch Psychiatry Clin Neurosci.19972472282339332905
   PubMed Web of Science ®Google Scholar
• MaesM.MeltzerHY.BosmansE.BergmansR.VandoolaegheE.RanjanR.DesnyderR.Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.J Affect Disord.1995343013098550956
   PubMed Web of Science ®Google Scholar
• PollakY.YirmiyaR.Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment.Int J Neuropsychopharmacol.2002538939912466037
   PubMed Web of Science ®Google Scholar
• MtabajiJP.MankuMS.HorrobinDF.Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2.Prostaglandins.197714125132897208
   PubMedGoogle Scholar
• YaronI.ShiraziI.JudovichR.LevartovskyD.CaspiD.YaronM.Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures.Arthritis Rheum.1999422561256810616001
   PubMedGoogle Scholar
• HestadKA.TonsethS.StoenCD.UelandT.AukrustP.Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy.J ECT.20031918318814657769
   PubMed Web of Science ®Google Scholar
• DimitrovS.LangeT.TiekenS.FehmHL.BornJ.Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans.Brain Behav Immun.20041834134815157951
   PubMed Web of Science ®Google Scholar
• SchwarczR.PellicciariR.Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.J Pharmacol Exp Ther.200230311012235226
   PubMed Web of Science ®Google Scholar
• HilmasC.PereiraEF.AlkondonM.RassoulpourA.SchwarczR.AlbuquerqueEX.The brain metabolite kynurenic acid inhibits alpha? nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.J Neurosci.2001217463747311567036
   PubMed Web of Science ®Google Scholar
• GrohmannU.FallarinoF.PuccettiP.Tolerance, DCs and tryptophan: much ado about IDO.Trends Immunol.20032424224812738417
   PubMed Web of Science ®Google Scholar
• TakikawaO.YoshidaR.KidoR.HayaishiO.Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase.J Biol Chem.1986261364836532419335
   PubMed Web of Science ®Google Scholar
• MillerCL.LlenosIC.DulayJR.BarilloMM.YolkenRH.WeisS.Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia.Neurobiol Dis.20041561862915056470
   PubMed Web of Science ®Google Scholar
• AloisiF.RiaF.AdoriniL.Regulation of T-cell responses by CNS antigenpresenting cells: different roles for microglia and astrocytes.Immunol Today.20002114114710689302
   PubMedGoogle Scholar
• KimYK.MyintAM.VerkerkR.ScharpeS.SteinbuschH.LeonardB.Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients.Neuropsychobiology.20095912312919390223
   PubMed Web of Science ®Google Scholar
• MellorAL.MunnDH.Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?Immunol Today.19992046947310500295
   PubMedGoogle Scholar
• MunnDH.ShafizadehE.AttwoodJT.BondarevI.PashineA.MellorAL.Inhibition of T cell proliferation by macrophage tryptophan catabolism.J Exp Med.19991891363137210224276
   PubMed Web of Science ®Google Scholar
• WeissG.MurrC.ZollerH.et al.Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells.Clin Exp Immunol.199911643544010361231
   PubMed Web of Science ®Google Scholar
• AlberatiGD.RicciardiCP.KohlerC.CesuraAM.Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells.J Neurochem.19966699610048769859
   PubMed Web of Science ®Google Scholar
• BraunD.LongmanRS.AlbertML.A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation.Blood.20051062375238115947091
   PubMed Web of Science ®Google Scholar
• MyintAM.KimYK.Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression.Med Hypotheses.20036151952514592780
   PubMed Web of Science ®Google Scholar
• ChiarugiA.CalvaniM.MeliE.TraggiaiE.MoroniF.Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages.J Neuroimmunol.200112019019811694334
   PubMed Web of Science ®Google Scholar
• LidbergL.BelfrageH.BertilssonL.EvendenMM.AsbergM.Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders.Acta Psychiatr Scand.200010139540210823300
   PubMed Web of Science ®Google Scholar
• MannJJ.MaloneKM.Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients.Biol Psychiatry.1997411621719018386
   PubMed Web of Science ®Google Scholar
• BonaccorsoS.MarinoV.PuzellaA.et al.Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.J Clin Psychopharmacol.200222869011799348
   PubMed Web of Science ®Google Scholar
• CapuronL.NeurauterG.MusselmanDL.et al.Interferon-alphainduced changes in tryptophan metabolism, relationship to depression and paroxetine treatment.Biol Psychiatry.20035490691414573318
   PubMed Web of Science ®Google Scholar
• AloisiF.PennaG.CeraseJ.MenendezIB.AdoriniL.IL-12 production by central nervous system microglia is inhibited by astrocytes.J Immunol.1997159160416129257819
   PubMed Web of Science ®Google Scholar
• RothermundtM.FalkaiP.PonathG.et al.Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.Mol Psychiatry.2004989789915241436
   PubMed Web of Science ®Google Scholar
• BayerTA.BusleiR.HavasL.FalkaiP.Evidence for activation of microglia in patients with psychiatric illnesses.Neurosci Lett.199927112612810477118
   PubMed Web of Science ®Google Scholar
• CotterD.ParianteC.RajkowskaG.Glial pathology in major psychiatric disorders. In Agam G, Belmaker RH, Everall I, eds.The Post-Mortern Brain in Psychiatric Research. Boston, MA: Kluwer Acad Pub;2002291324
   Google Scholar
• RajkowskaG.Depression: what we can learn from postmortem studies.Neuroscientist.2003927328412934710
   PubMed Web of Science ®Google Scholar
• Miguel-HidalgoJJ.BaucomC.DilleyG.et al.Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder.Biol Psychiatry.20004886187311063981
   PubMed Web of Science ®Google Scholar
• DavisS.ThomasA.PerryR.OakleyA.KalariaRN.O'BrienJT.Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study.J Neurol Neurosurg Psychiatry.20027355656012397151
   PubMed Web of Science ®Google Scholar
• RajkowskaG.Astroglia in the cortex of schizophrenics: histopathology finding.World J Biol Psychiatry.2005674
   Google Scholar
• ChoudaryPV.MolnarM.EvansSJ.et al.Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.Proc Natl Acad Sci USA.2005102156531565816230605
   PubMed Web of Science ®Google Scholar
• DanboltNC.Glutamate uptake.Prog Neurobiol.200165110511369436
   PubMed Web of Science ®Google Scholar
• SanacoraG.GueorguievaR.EppersonCN.et al.Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.Arch Gen Psychiatry.20046170571315237082
   PubMed Web of Science ®Google Scholar
• HeyesMP.ChenCY.MajorEO.SaitoK.Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.Biochem J.19973263513569291104
   PubMed Web of Science ®Google Scholar
• KissC.Ceresoli-BorroniG.GuidettiP.ZielkeCL.ZielkeHR.SchwarczR.Kynurenate production by cultured human astrocytes.J Neural Transm.200311011412541009
   PubMed Web of Science ®Google Scholar
• GuilleminGJ.KerrSJ.SmytheGA.et al.Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection.J Neurochem.20017884285311520905
   PubMed Web of Science ®Google Scholar
• ChiarugiA.CarpenedoR.MoroniF.Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase.J Neurochem.1996676926988764597
   PubMed Web of Science ®Google Scholar
• SaitoK.CrowleyJS.MarkeySP.HeyesMP.A mechanism for increased quinolinic acid formation following acute systemic immune stimulation.J Biol Chem.199326815496155038340378
   PubMed Web of Science ®Google Scholar
• HeyesMP.SaitoK.LacknerA.WileyCA.AchimCL.MarkeySP.Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques.FASEB J.1998128818969657528
   PubMed Web of Science ®Google Scholar
• HeyesMP.SaitoK.CrowleyJS.Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.Brain.1992115124912731422788
   PubMed Web of Science ®Google Scholar
• WichersMC.KoekGH.RobaeysG.VerkerkR.ScharpeS.MaesM.IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.Mol Psychiatry.20051053854415494706
   PubMed Web of Science ®Google Scholar
• HeyesMP.BrewBJ.MartinA.et al.Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status.Ann Neurol.1991292022091826418
   PubMed Web of Science ®Google Scholar
• LapinIP.Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety.Adv Exp Med Biol.200352712112515206724
   PubMed Web of Science ®Google Scholar
• ChenQ.SurmeierDJ.ReinerA.NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization.Exp Neurol.199915928329610486197
   PubMed Web of Science ®Google Scholar
• SchwielerL.ErhardtS.ErhardtC.EngbergG.Prostaglandin-mediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms.J Neural Transm.200511286387215517427
   PubMed Web of Science ®Google Scholar
• MüllerN.RiedelM.ScheppachC.et al.Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.Am J Psychiatry.20021591029103412042193
   PubMed Web of Science ®Google Scholar
• MüllerN.UlmschneiderM.ScheppachC.et al.COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.Eur Arch Psychiatiy Clin Neurosci.20042541422
   PubMed Web of Science ®Google Scholar
• MüllerN.RiedelM.DehningS.et al.Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease?Neuropsychopharmacology.200429176
   Web of Science ®Google Scholar
• CasoliniP.CatalaniA.ZuenaAR.AngelucciL.Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.J Neurosci Res.20026833734312111864
   PubMed Web of Science ®Google Scholar
• ZhangY.Chun ChenD.Long TanY.ZhouDF.A double-blind, placebo-controlled trial of celecoxib addes to risperidone in first-episode and drugnaive patients with schizophrenia [abstract].Eur Arch Psychiatry Clin Neurosci.2006256(suppl 2) II/50
   Google Scholar
• AkhondzadehS.TabatabaeeM.AminiH.Ahmadi AbhariSA.AbbasiSH.BehnamB.Celecoxib as adjunctive therapy in schizophrenia: a doubleblind, randomized and placebo-controlled trial.Schizophr Res.20079017918517208413
   PubMed Web of Science ®Google Scholar
• RapaportMH.DelrahimKK.BreseeCJ.MadduxRE.AhmadpourO.DolnakD.Celecoxib augmentation of continuously ill patients with schizophrenia.Biol Psychiatry.2005571594159615953498
   PubMed Web of Science ®Google Scholar
• HuF.WangX.PaceTW.WuH.MillerAH.Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.Moi Psychiatry.20051042642815700047
   PubMed Web of Science ®Google Scholar
• SongC.LeonardBE.Fundamentals of Psychoneuroimmunology.Chichester, NY: J Wiley and Sons;2000
   Google Scholar
• CaoC.MatsumuraK.OzakiM.WatanabeY.Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells.J Neurosci.1999197167259880592
   PubMed Web of Science ®Google Scholar
• SandriniM.VitaleG.PiniLA.Effect of rofecoxib on nociception and the serotonin system in the rat brain,inflamm Res.20025115415912005206
   PubMed Web of Science ®Google Scholar
• Salzberg-BrenhouseHC.ChenEY.EmerichDF.et al.Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration.J Pharmacol Exp Ther.200330621822812676885
   PubMed Web of Science ®Google Scholar
• MyintAM.SteinbuschHW.GoegheganL.LuchtmanD.KimYK.LeonardBE.Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.Neuroimmunomoduiation.2007146571
   PubMed Web of Science ®Google Scholar
• BrunelloN.AlboniS.CaponeG.et al.Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression.Int Clin Psychopharmacol.20062121922516687993
   PubMed Web of Science ®Google Scholar
• MüllerN.SchwarzMJ.DehningS.et al.The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a doubleblind, randomized, placebo controlled, add-on pilot study to reboxetine.Mol Psychiatry.20061168068416491133
   PubMed Web of Science ®Google Scholar
• MendlewiczJ.KriwinP.OswaldP.SoueryD.AlboniS.BrunelloN.Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study.Int Clin Psychopharmacol.20062122723116687994
   PubMed Web of Science ®Google Scholar